Literature DB >> 29234190

Can Non-Selective Beta-Blockers (NSBBs) Prevent Enlargement of Small Esophageal Varices in Patients with Cirrhosis? A Meta-analysis.

Ashish Kumar1, Praveen Sharma1, Shrihari A Anikhindi1, Ritesh Prajapati1, Rachit Agarwal1, Bhupendra Sharma1, Naresh Bansal1, Vikas Singla1, Anil Arora1.   

Abstract

BACKGROUND: Non-selective beta-blockers (NSBBs) are recommended for prophylaxis of first variceal bleeding in patients of cirrhosis with large esophageal varices. However, the data is conflicting whether NSBBs can also prevent growth of small esophageal varices to large size. AIM: To perform a meta-analysis of the randomized clinical trials comparing NSBBs with placebo for prevention of development of large esophageal varices in patients of cirrhosis with small esophageal varices.
METHODS: The PubMed, EMBASE, Science Direct, and Cochrane library databases were searched for relevant papers. A meta-analysis was performed using risk ratios (RRs) with 95% confidence interval (CI) as the effect sizes.
RESULTS: Overall, 314 trials were initially retrieved from the database searches, of which five randomized controlled trials were included in the meta-analysis. The incidence of development of large varices (RR = 0.91, 95%CI: 0.29-2.86; P = 0.87) was similar between NSBB and placebo groups. However, the heterogeneity among studies was significant (P < 0.01) with an I2 of 93%. The incidences of first variceal bleeding (RR = 0.72, 95%CI: 0.25-2.12; P = 0.55) and death (RR = 0.76, 95%CI: 0.50-1.15; P = 0.19) were also similar between NSBB and placebo groups; with no heterogeneity. The incidence of adverse events was significantly higher in the NSBB group compared with the placebo group (RR = 4.66, 95%CI: 1.36-15.91; P = 0.01).
CONCLUSION: The results of this meta-analysis indicate that NSBBs are not effective in preventing growth of small varices and may lead to significant adverse effects. Hence, NSBBs should not be recommended for cirrhotic patients with small varices.

Entities:  

Keywords:  CI, confidence interval; NIHR, National Institute for Health Research; NSBB, non-selective beta-blockers; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, Prospective Register of Systematic Reviews; RR, risk ratio; acute variceal bleeding; cirrhosis; esophageal varices; non-selective beta-blockers; portal hypertension

Year:  2017        PMID: 29234190      PMCID: PMC5715455          DOI: 10.1016/j.jceh.2017.09.003

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  31 in total

1.  A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.

Authors:  Carlo Merkel; Renato Marin; Paolo Angeli; Pierluigi Zanella; Martina Felder; Elisabetta Bernardinello; Giorgio Cavallarin; Massimo Bolognesi; Carlo Donada; Barbara Bellini; Pierluigi Torboli; Angelo Gatta
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

2.  Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis.

Authors:  Rosario Gonzalez; Javier Zamora; Judith Gomez-Camarero; Luis-Miguel Molinero; Rafael Bañares; Agustín Albillos
Journal:  Ann Intern Med       Date:  2008-07-15       Impact factor: 25.391

Review 3.  Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis.

Authors:  Xing-Shun Qi; Yong-Xin Bao; Ming Bai; Wen-Da Xu; Jun-Na Dai; Xiao-Zhong Guo
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension.

Authors:  P Calés; F Oberti; J L Payen; S Naveau; D Guyader; P Blanc; A Abergel; P Bichard; J M Raymond; V Canva-Delcambre; D Vetter; D Valla; M Beauchant; A Hadengue; B Champigneulle; J P Pascal; T Poynard; D Lebrec
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-07       Impact factor: 2.566

5.  Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial.

Authors:  D Lebrec; T Poynard; J P Capron; P Hillon; P Geoffroy; D Roulot; J C Chaput; B Rueff; J P Benhamou
Journal:  J Hepatol       Date:  1988-08       Impact factor: 25.083

6.  Incidence and natural history of small esophageal varices in cirrhotic patients.

Authors:  Manuela Merli; Giorgia Nicolini; Stefania Angeloni; Vittorio Rinaldi; Adriano De Santis; Carlo Merkel; Adolfo Francesco Attili; Oliviero Riggio
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

7.  Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.

Authors:  H O Conn; N D Grace; J Bosch; R J Groszmann; J Rodés; S C Wright; D S Matloff; G Garcia-Tsao; R L Fisher; M Navasa
Journal:  Hepatology       Date:  1991-05       Impact factor: 17.425

8.  Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial.

Authors:  Shiv Kumar Sarin; Smruti Ranjan Mishra; Praveen Sharma; Barjesh Chander Sharma; Ashish Kumar
Journal:  Hepatol Int       Date:  2012-03-10       Impact factor: 6.047

9.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

10.  Propranolol--a medical treatment for portal hypertension?

Authors:  D Lebrec; O Nouel; M Corbic; J P Benhamou
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

View more
  4 in total

1.  Management of portal hypertensive upper gastrointestinal bleeding: Report of the Coorg Consensus workshop of the Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding.

Authors:  Shivaram P Singh; Manav Wadhawan; Subrat K Acharya; Sawan Bopanna; Kaushal Madan; Manoj K Sahoo; Naresh Bhat; Sri P Misra; Ajay Duseja; Amar Mukund; Anil C Anand; Ashish Goel; Bonthala S Satyaprakash; Joy Varghese; Manas K Panigrahi; Manu Tandan; Mihir K Mohapatra; Pankaj Puri; Pravin M Rathi; Rajkumar P Wadhwa; Sunil Taneja; Varghese Thomas; Vikram Bhatia
Journal:  Indian J Gastroenterol       Date:  2021-12-10

Review 2.  Overview of Complications in Cirrhosis.

Authors:  Madhumita Premkumar; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-05-14

3.  Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.

Authors:  Manoj Kumar; Sumit Kainth; Ashok Choudhury; Rakhi Maiwall; Lalita G Mitra; Vandana Saluja; Prashant Mohan Agarwal; Saggere Muralikrishna Shasthry; Ankur Jindal; Ankit Bhardwaj; Guresh Kumar; Shiv K Sarin
Journal:  Hepatol Int       Date:  2019-09-20       Impact factor: 6.047

Review 4.  Current and future pharmacological therapies for managing cirrhosis and its complications.

Authors:  David Kockerling; Rooshi Nathwani; Roberta Forlano; Pinelopi Manousou; Benjamin H Mullish; Ameet Dhar
Journal:  World J Gastroenterol       Date:  2019-02-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.